ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
ERYTECH to Present at the JMP Securities Hematology Summit
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting
ERYTECH to Present at Jefferies Virtual Healthcare Conference
ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting
ERYTECH Secures Euro10 Million in Non-Dilutive Financing, Guaranteed by the French Government
ERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.